GENALIVE MEDICAL COMPANY (GENALIVE)
Genalive is a specialized, large-scale genetic and clinical laboratory in Riyadh, Saudi Arabia, and one of the largest private molecular and sequencing labs in the Kingdom.
The facility spans over 4,000 square meters and was launched as a first-of-its-kind advanced genetic testing center.
Genalive was officially launched on June 7, 2023, under Commercial Registration No. (1010849621).
The laboratory provides:
It was established through a partnership between Tibbiyah and BGI Health, enabling state-of-the-art techniques, high-throughput sequencing, and AI-driven analysis.
- Comprehensive genetic testing including prenatal, oncology-related, hereditary diseases, and pharmacogenetics
- Routine clinical laboratory services such as hematology, chemistry, and immunochemistry
- Advanced sequencing and bioinformatics capabilities powered by technologies from BGI Group
Genalive mission supports Saudi Vision 2030 by:
- Localizing genetic testing
- Enhancing early detection of genetic diseases
- Supporting precision medicine and scientific innovation within the Kingdom
Ownership structure for Genalive Medical Company
| Shareholder | Number of Shares | Share Value (SAR) | Total Share Value (SAR) | Ownership (%) |
|---|---|---|---|---|
| Tibbiyah (Arabian International Healthcare Holding Company) | 6,725,000 | 10 | 67,250,000 | 50.00% |
| BGI Almanahil Health for Medical Services | 6,725,000 | 10 | 67,250,000 | 50.00% |
| Total | 13,450,000 | 10 | 134,500,000 | 100.00% |